Oncology Institute (NASDAQ:STLN) Issues Quarterly Earnings Results

Oncology Institute (NASDAQ:STLN) released its quarterly earnings data on Thursday. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06), Zacks reports. The company had revenue of $169.77 million for the quarter.

Here are the key takeaways from Oncology Institute’s conference call:

• Third-quarter revenue rose 24.3% year over year to $169.8 million, and Adjusted EBITDA was positive $3.4 million, above the company’s guidance. Starling reaffirmed full-year 2026 Adjusted EBITDA positivity and expects $4 million–$6 million for the year.
• Specialty pharmacy revenue increased 44% to $109.3 million, with gross margin reaching 24.2%. Management attributed part of the margin strength to rebates and favorable drug pricing that may not recur, and expects margins to normalize in the high teens.
• Capitated revenue grew 39.5% to $28.7 million, but expansion with Florida health plan partners has been delayed for timing and operational reasons. Starling said it still expects capitated revenue to grow 100% in 2027, while reserving full guidance until the first quarter.
• Early Starling Nexus results showed more than 99.2% utilization-management compliance across over 4,000 Florida authorizations, with average decisions in 13 hours. The portal is live across delegated markets, including Oregon, and the company sees potential to expand pharmacy and other ancillary services through it.
• Cash flow improved substantially: operating cash flow was positive $19.9 million for the first nine months, versus a $27.8 million use a year earlier, and nine-month free cash flow was positive $20.2 million. The company ended the quarter with $36.9 million in cash and guided to full-year free cash flow of $5 million–$10 million.

Oncology Institute Price Performance

Shares of NASDAQ:STLN traded down $3.08 during trading on Friday, reaching $3.62. The stock had a trading volume of 23,895,218 shares, compared to its average volume of 1,268,476. The firm has a 50-day simple moving average of $6.43. The company has a market cap of $357.80 million, a PE ratio of -12.48 and a beta of 0.44. Oncology Institute has a 52 week low of $2.32 and a 52 week high of $7.13.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. B. Riley Financial reaffirmed a “buy” rating and issued a $10.00 price objective (down from $11.00) on shares of Oncology Institute in a report on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oncology Institute in a research report on Tuesday. Needham & Company LLC raised their price target on shares of Oncology Institute from $7.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, October 14th. Finally, BTIG Research upped their target price on Oncology Institute from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $9.75.

Insiders Place Their Bets

In related news, Director Brad Hively sold 298,853 shares of the firm’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $6.51, for a total value of $1,945,533.03. Following the transaction, the director owned 411,976 shares in the company, valued at $2,681,963.76. This trade represents a 42.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Jorey Chernett acquired 12,000 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The stock was acquired at an average price of $6.54 per share, for a total transaction of $78,480.00. Following the completion of the acquisition, the insider directly owned 10,660,858 shares of the company’s stock, valued at $69,722,011.32. This trade represents a 0.11% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders own 4.40% of the company’s stock.

Oncology Institute News Roundup

Here are the key news stories impacting Oncology Institute this week:

• Positive Sentiment: BTIG Research raised its price target to $10 from $9 and maintained a “buy” rating, indicating substantial potential upside in its view. TickerReport article
• Neutral Sentiment: B. Riley reaffirmed its “buy” rating but lowered its target to $10 from $11, signaling continued optimism alongside a more cautious valuation. B. Riley rating
• Negative Sentiment: For the third quarter, the company reported a loss of $0.13 per share, worse than the $0.07 loss analysts expected, although the loss narrowed from $0.14 a year earlier. Revenue was $169.77 million and beat estimates. Quarterly results coverage
• Negative Sentiment: Full-year 2026 revenue guidance of $650 million–$660 million came in below the $665 million consensus estimate, raising concern about the company’s growth outlook. Company results and guidance

Oncology Institute Company Profile

The Oncology Institute is a value-based oncology care company focused on delivering comprehensive cancer treatment and related services through community-based care settings. Its model is designed to support patients throughout the cancer-care journey while coordinating treatment among oncologists, primary-care providers, specialists and other healthcare professionals.

The company provides medical oncology and hematology services, cancer screening and diagnosis, treatment planning, chemotherapy and other infusion therapies, supportive care, survivorship services and care-management programs.